Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trials
4 recruiting trials for Neovascular Age-Related Macular Degeneration (nAMD). Eligibility criteria explained in plain English.
TrialFinderData lists 4 Neovascular Age-Related Macular Degeneration (nAMD) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 3 is the largest group at 67% (2 studies); the largest phase groups are Phase 3: 2, Phase 2: 1.
Research is led by Peking University People's Hospital (1), Innostellar Biotherapeutics Co.,Ltd (1), EyebioKorea, Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Aflibercept 8mg (drug, 1 trial), followed by LX102, Aflibercept.
Track Neovascular Age-Related Macular Degeneration (nAMD) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Real-world Study of Aflibercept 8 mg in nAMD
The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular...
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular...
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the...
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related...
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Neovascular Age-Related Macular Degeneration (nAMD), with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Neovascular Age-Related Macular Degeneration (nAMD), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Neovascular Age-Related Macular Degeneration (nAMD), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.